Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 128 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Dry (Atrophic) Macular Degeneration - Pipeline Review, H1 2015', provides an overview of the Dry (Atrophic) Macular Degeneration's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dry (Atrophic) Macular Degeneration
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Dry (Atrophic) Macular Degeneration and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Dry (Atrophic) Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dry (Atrophic) Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dry (Atrophic) Macular Degeneration
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dry (Atrophic) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Dry (Atrophic) Macular Degeneration Overview 9
Therapeutics Development 10
Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview 10
Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis 11
Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies 12
Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes 14
Dry (Atrophic) Macular Degeneration - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Dry (Atrophic) Macular Degeneration - Products under Development by Companies 19
Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes 21
Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development 22
Acucela Inc. 22
Alexion Pharmaceuticals, Inc. 23
Alimera Sciences, Inc. 24
Apellis Pharmaceuticals, Inc. 25
Benitec Biopharma Limited 26
Bioheart, Inc. 27
Catalyst Biosciences, Inc. 28
Cell Cure Neurosciences, Ltd. 29
Eleven Biotherapeutics Inc. 30
Foamix Pharmaceuticals Ltd. 31
Genentech, Inc. 32
GenSight Biologics SA 33
GlaxoSmithKline plc 34
Icon Bioscience, Inc. 35
MacuCLEAR, Inc. 36
Neurotech Pharmaceuticals, Inc. 37
Ocata Therapeutics, Inc. 38
Ophthotech Corp. 39
pSivida Corp. 40
Sun Pharma Advanced Research Company Ltd. 41
Dry (Atrophic) Macular Degeneration - Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Target 43
Assessment by Mechanism of Action 45
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
AdipoCell - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
APL-2 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
avacincaptad pegol sodium - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
EBI-028 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
eculizumab - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
emixustat hydrochloride - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
fluocinolone acetonide - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Gene Therapy for Ocular Diseases - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
GS-020 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
GSK-933776 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
HMR-59 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ICR-14967 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
lampalizumab - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
MA09-hRPE - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
MC-1101 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
methotrexate - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
minocycline Gel - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
NM-9405 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
NT-501 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
OpRegen - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
OpRegen Plus - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
RC-1 Alpha - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Recombinant Enzymes to Inhibit Complement C3 for Dry Age-Related Macular Degeneration - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
RST-001 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Small Molecules for Age Related Macular Degeneration - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Small Molecules for AMD - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Small Molecules to Inhibit NADPH Oxidase for Dry Macular Degeneration - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Synthetic Peptides to Activate CD36 Receptor for Cardiovascular Diseases and Macular Degeneration - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
TT-231 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Dry (Atrophic) Macular Degeneration - Recent Pipeline Updates 92
Dry (Atrophic) Macular Degeneration - Dormant Projects 120
Dry (Atrophic) Macular Degeneration - Discontinued Products 122
Dry (Atrophic) Macular Degeneration - Product Development Milestones 123
Featured News & Press Releases 123
Dec 17, 2013: Bioheart Announces Clinical Study for Dry Macular Degeneration 123
Oct 18, 2013: Alimera Sciences Receives Complete Response Letter For ILUVIEN 123
Oct 01, 2013: Roche to present data on Lampalizumab at investor event 124
Aug 27, 2013: Roche's lampalizumab phase II data shows benefit in patients with the advanced form of dry age-related macular degeneration 124
Feb 15, 2013: OgenX Therapeutics Announces Presentation Of RAVEN-1 Trial Final Results At Snowmass Ophthalmology Conference 126
Appendix 127
Methodology 127
Coverage 127
Secondary Research 127
Primary Research 127
Expert Panel Validation 127
Contact Us 127
Disclaimer 128

List of Tables

Number of Products under Development for Dry (Atrophic) Macular Degeneration, H1 2015 10
Number of Products under Development for Dry (Atrophic) Macular Degeneration - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Comparative Analysis by Unknown Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H1 2015 21
Dry (Atrophic) Macular Degeneration - Pipeline by Acucela Inc., H1 2015 22
Dry (Atrophic) Macular Degeneration - Pipeline by Alexion Pharmaceuticals, Inc., H1 2015 23
Dry (Atrophic) Macular Degeneration - Pipeline by Alimera Sciences, Inc., H1 2015 24
Dry (Atrophic) Macular Degeneration - Pipeline by Apellis Pharmaceuticals, Inc., H1 2015 25
Dry (Atrophic) Macular Degeneration - Pipeline by Benitec Biopharma Limited, H1 2015 26
Dry (Atrophic) Macular Degeneration - Pipeline by Bioheart, Inc., H1 2015 27
Dry (Atrophic) Macular Degeneration - Pipeline by Catalyst Biosciences, Inc., H1 2015 28
Dry (Atrophic) Macular Degeneration - Pipeline by Cell Cure Neurosciences, Ltd., H1 2015 29
Dry (Atrophic) Macular Degeneration - Pipeline by Eleven Biotherapeutics Inc., H1 2015 30
Dry (Atrophic) Macular Degeneration - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 31
Dry (Atrophic) Macular Degeneration - Pipeline by Genentech, Inc., H1 2015 32
Dry (Atrophic) Macular Degeneration - Pipeline by GenSight Biologics SA, H1 2015 33
Dry (Atrophic) Macular Degeneration - Pipeline by GlaxoSmithKline plc, H1 2015 34
Dry (Atrophic) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H1 2015 35
Dry (Atrophic) Macular Degeneration - Pipeline by MacuCLEAR, Inc., H1 2015 36
Dry (Atrophic) Macular Degeneration - Pipeline by Neurotech Pharmaceuticals, Inc., H1 2015 37
Dry (Atrophic) Macular Degeneration - Pipeline by Ocata Therapeutics, Inc., H1 2015 38
Dry (Atrophic) Macular Degeneration - Pipeline by Ophthotech Corp., H1 2015 39
Dry (Atrophic) Macular Degeneration - Pipeline by pSivida Corp., H1 2015 40
Dry (Atrophic) Macular Degeneration - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2015 41
Assessment by Monotherapy Products, H1 2015 42
Number of Products by Stage and Target, H1 2015 44
Number of Products by Stage and Mechanism of Action, H1 2015 46
Number of Products by Stage and Route of Administration, H1 2015 48
Number of Products by Stage and Molecule Type, H1 2015 50
Dry (Atrophic) Macular Degeneration Therapeutics - Recent Pipeline Updates, H1 2015 92
Dry (Atrophic) Macular Degeneration - Dormant Projects, H1 2015 120
Dry (Atrophic) Macular Degeneration - Dormant Projects (Contd..1), H1 2015 121
Dry (Atrophic) Macular Degeneration - Discontinued Products, H1 2015 122